Migraine Disability, Healthcare Utilization, and Expenditures Following Treatment in a Tertiary Headache Center

Freitag, Frederick G.; Lyss, Heidi; Nissan, George R.

doi:10.1080/08998280.2013.11929007

Cited by 17 publications

(12 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The aim of any prophylactic treatment is to reduce disability and to restore functional ability by decreasing the frequency and severity of migraine [7, 40]. Studies on preventive pharmacologic treatment in migraine patients have shown that decreasing the frequency of migraine and the number of headache days significantly improves measures of migraine disability, impact of migraine, HRQoL [41], absenteeism and presenteeism [42], HRU, and costs [43]. In a study by Santoro et al [44], medications significantly reduced MHDs compared to baseline and also reduced the intensity from Migraine Disability Assessment Scale (MIDAS) grade IV from the sixth month of treatment in patients with chronic migraine.…”

Section: Discussionmentioning

confidence: 99%

Associations Between Headache-Free Days and Patient-Reported Outcomes Among Migraine Patients: A Cross-Sectional Analysis of Survey Data in Europe

Doane

Gupta

et al. 2019

Pain Ther

View full text Add to dashboard Cite

IntroductionMigraine imposes a substantial burden on patients, society, and healthcare systems. This study aimed to assess the associations between the number of headache-free days (HFDs) and health-related quality of life (HRQoL), work productivity and activity impairment (WPAI), and healthcare resource utilization (HRU) in patients with migraine in the EU5 (France, Germany, Italy, Spain, and the United Kingdom).MethodsThis retrospective cross-sectional study collected survey responses from adults aged ≥ 18 years from the 2017 National Health and Wellness Survey (N = 62,000). Migraine patients with a physician’s diagnosis of migraine and who had experienced at least 4 monthly headache days in the prior month were included (N = 1569). Number of HFDs was compared with Short-Form 12-Item Survey Instrument, version 2 (SF-12v2) physical and mental component summary scores (PCS and MCS), Short-Form-6D (SF-6D) and EuroQoL-5D (EQ-5D) scores, WPAI, and HRU in migraine patients. Correlation analyses were conducted to test the bivariate associations, whereas generalized linear models were used for multivariable analyses.ResultsAn increase of 1 HFD was associated with average increases of 0.171, 0.306, 0.003, and 0.008 points for MCS, PCS, SF-6D utility score, and EQ-5D index score, respectively (p < 0.001 for all). Extrapolating the results to a tenfold increase in monthly HFDs corresponded to clinically meaningful increases in PCS and EQ-5D scores. An increase of 1 HFD was associated with expected average decreases in absenteeism of 3.9% and presenteeism of 2.1%. Further, an increase of 1 HFD was associated with expected decreases in HCP visits and neurologist visits of 1.0% and 4.7%, respectively.ConclusionAn increase in the number of HFDs was associated with better health-related outcomes in patients suffering from migraine. Further, the results demonstrate a need for more effective treatments that can reduce migraine frequency and thus improve HRQoL, increase work productivity, and reduce both activity impairment and HRU.FundingNovartis Pharma AG, Switzerland.

show abstract

Section: Discussionmentioning

confidence: 99%

Associations Between Headache-Free Days and Patient-Reported Outcomes Among Migraine Patients: A Cross-Sectional Analysis of Survey Data in Europe

Doane

Gupta

et al. 2019

Pain Ther

View full text Add to dashboard Cite

show abstract

“…Besides TPE, other interventions, such as physical therapy [66,67] or peripheral nerve stimulation, are also able to reduce disability in those complex treatment patients [68,69]. In this way, some authors suggest that earlier tertiary‐level intervention may avoid the complications of migraine that occur in some patients and the increasing costs and utilization of care associated with higher disability [70].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of Therapeutic Patient Education for Adults with Migraine. A Systematic Review and Meta-Analysis of Randomized Controlled Trials

et al. 2014

View full text Add to dashboard Cite

show abstract

“…20 Each employee with frequent migraine costs employers thousands of dollars every year, with estimates between $2,400 and $7,000 for women and $4,000 and $13,000 for men. 21,22 Developing novel treatments for migraine prevention with better efficacy or tolerability profiles is a priority for improving migraine outcomes. One promising approach targets the calcitonin gene-related peptide (CGRP, a sensory neuropeptide implicated in migraine pathogenesis) pathway.…”

Section: Introductionmentioning

confidence: 99%

Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective

Lipton

Brennan

Palmer

et al. 2018

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

Migraine Disability, Healthcare Utilization, and Expenditures Following Treatment in a Tertiary Headache Center

Cited by 17 publications

References 13 publications

Associations Between Headache-Free Days and Patient-Reported Outcomes Among Migraine Patients: A Cross-Sectional Analysis of Survey Data in Europe

Associations Between Headache-Free Days and Patient-Reported Outcomes Among Migraine Patients: A Cross-Sectional Analysis of Survey Data in Europe

Effectiveness of Therapeutic Patient Education for Adults with Migraine. A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective

Contact Info

Product

Resources

About